U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C24H33O5.Na
Molecular Weight 424.5056
Optical Activity UNSPECIFIED
Defined Stereocenters 8 / 8
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of DEHYDROCHOLATE SODIUM

SMILES

[Na+].C[C@H](CCC([O-])=O)[C@H]1CC[C@H]2[C@H]3[C@H](CC(=O)[C@]12C)[C@@]4(C)CCC(=O)C[C@H]4CC3=O

InChI

InChIKey=FKJIJBSJQSMPTI-CAOXKPNISA-M
InChI=1S/C24H34O5.Na/c1-13(4-7-21(28)29)16-5-6-17-22-18(12-20(27)24(16,17)3)23(2)9-8-15(25)10-14(23)11-19(22)26;/h13-14,16-18,22H,4-12H2,1-3H3,(H,28,29);/q;+1/p-1/t13-,14+,16-,17+,18+,22+,23+,24-;/m1./s1

HIDE SMILES / InChI

Molecular Formula C24H33O5
Molecular Weight 401.5158
Charge -1
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 8 / 8
E/Z Centers 0
Optical Activity UNSPECIFIED

Molecular Formula Na
Molecular Weight 22.98976928
Charge 1
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: description was created based on several sources, including http://patft.uspto.gov/netacgi/nph-Parser?Sect2=PTO1&Sect2=HITOFF&p=1&u=/netahtml/PTO/search-bool.html&r=1&f=G&l=50&d=PALL&RefSrch=yes&Query=PN/5935948

Sodium dehydrocholate is a hydrocholeretic and is used to study biliary excretion.

CNS Activity

Curator's Comment: In rats, sodium dehydrocholate disrupts the blood-brain barrier for a period of over 3 days.

Originator

Curator's Comment: Hammarsten in 1881 succeeded in converting cholic acid into dehydrocholic acid

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Target ID: Anionic polypeptide fraction (APF) secretion in bile
Target ID: Q99626
Gene ID: 1045.0
Gene Symbol: CDX2
Target Organism: Homo sapiens (Human)
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Diagnostic
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
Primary
Decholinum

Approved Use

Unknown
Doses

Doses

DosePopulationAdverse events​
250 mg 3 times / day multiple, oral
Dose: 250 mg, 3 times / day
Route: oral
Route: multiple
Dose: 250 mg, 3 times / day
Sources:
unhealthy, 36-75
Health Status: unhealthy
Age Group: 36-75
Sex: M+F
Sources:
Other AEs: Nausea, Diarrhea...
Other AEs:
Nausea (1 patient)
Diarrhea (1 patient)
Weight loss (1 patient)
Pain in hand (1 patient)
Sources:
AEs

AEs

AESignificanceDosePopulation
Diarrhea 1 patient
250 mg 3 times / day multiple, oral
Dose: 250 mg, 3 times / day
Route: oral
Route: multiple
Dose: 250 mg, 3 times / day
Sources:
unhealthy, 36-75
Health Status: unhealthy
Age Group: 36-75
Sex: M+F
Sources:
Nausea 1 patient
250 mg 3 times / day multiple, oral
Dose: 250 mg, 3 times / day
Route: oral
Route: multiple
Dose: 250 mg, 3 times / day
Sources:
unhealthy, 36-75
Health Status: unhealthy
Age Group: 36-75
Sex: M+F
Sources:
Pain in hand 1 patient
250 mg 3 times / day multiple, oral
Dose: 250 mg, 3 times / day
Route: oral
Route: multiple
Dose: 250 mg, 3 times / day
Sources:
unhealthy, 36-75
Health Status: unhealthy
Age Group: 36-75
Sex: M+F
Sources:
Weight loss 1 patient
250 mg 3 times / day multiple, oral
Dose: 250 mg, 3 times / day
Route: oral
Route: multiple
Dose: 250 mg, 3 times / day
Sources:
unhealthy, 36-75
Health Status: unhealthy
Age Group: 36-75
Sex: M+F
Sources:
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG

OverviewOther

Other InhibitorOther SubstrateOther Inducer




Drug as perpetrator​
Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
Surgical outcome in relation to duct size at the porta hepatis and the use of cholagogues in patients with biliary atresia.
2011-05-13
Chemical genetic screen identifies lithocholic acid as an anti-aging compound that extends yeast chronological life span in a TOR-independent manner, by modulating housekeeping longevity assurance processes.
2010-07
Thermodynamic and elastic fluctuation analysis of Langmuir mixed monolayers composed by dehydrocholic acid (HDHC) and didodecyldimethylammonium bromide (DDAB).
2010-01-01
Study on bioactive compounds of in vitro cultured Calculus Suis and natural Calculus Bovis.
2009-12
Protective effect of bile acid derivatives in phalloidin-induced rat liver toxicity.
2009-08-15
Acidic and basic solutions dissolve protein plugs made of lithostathine complicating choledochal cyst/pancreaticobiliary maljunction.
2009-07
A new approach for diagnosis of hepatolithiasis: magnetic resonance cholangiopancreatography: potential usefulness of dehydrocholic acid (DHCA) administration in the evaluation of hepatolithiasis.
2008-12-24
Magnetic resonance cholangiopancreatography: potential usefulness of dehydrocholic acid (DHCA) administration in the evaluation of biliary disease.
2008-07-11
Magnetic resonance cholangiopancreatography: potential usefulness of dehydrocholic acid (DHCA) administration in the evaluation of anastomotic site.
2008-05-30
Spread mixed monolayers of deoxycholic and dehydrocholic acids at the air-water interface, effect of subphase pH. Characterization by axisymmetric drop shape analysis.
2008-01
Aqueous sodium dehydrocholate-sodium deoxycholate mixtures at low concentration.
2007-10-15
Determination of critical micellar concentrations of cholic acid and its keto derivatives.
2007-10-01
Regio- and stereoselective reductions of dehydrocholic acid.
2006-06
Bile acids directly augment caudal related homeobox gene Cdx2 expression in oesophageal keratinocytes in Barrett's epithelium.
2006-01
A novel insulin derivative chemically modified with dehydrocholic acid: synthesis, characterization and biological activity.
2005-08
Sterol-derived hormone(s) controls entry into diapause in Caenorhabditis elegans by consecutive activation of DAF-12 and DAF-16.
2004-10
Lasting blood-brain barrier disruption induces epileptic focus in the rat somatosensory cortex.
2004-09-08
Choleretic activity and biliary elimination of lipids and bile acids induced by an artichoke leaf extract in rats.
2002-12
Spasmocanulase in irritable bowel syndrome.
2002-09
Carbonic anhydrase inhibitors. Preparation of potent sulfonamides inhibitors incorporating bile acid tails.
2002-06-17
Choledocholithiasis in an infant of extremely low birthweight.
2002-04
Anodic electrochemical oxidation of cholic acid.
2001-02
Effects of sodium ursodeoxycholate, hyodeoxycholate and dehydrocholate on cholesterol and bile acid metabolism in rats.
1983-05
Influence of dehydrocholate sodium on the biliary reabsorption of sulfobromophtalein sodium from the rat biliary tree after retrograde intrabilary injection.
1976-08-15
Patents

Sample Use Guides

The usual daily dose of dehydrocholic acid may be 250-750 mg per day, dehydrocholic acid may be administered in doses of 250 mg ingested once or twice per day, usually before meals or, for persons with sensitive gastrointestinal tracts, 125 mg two or three times per day before meals.
Route of Administration: Oral
Dehydrocholic acid (DHCA) was added to CV-1, monkey kidney cell line, TT (a human oesophageal squamous carcinoma), HT-29 (a human colon carcinoma) at 100 uM to afford a ~4-fold increase in CDX2 expression.
Substance Class Chemical
Created
by admin
on Mon Mar 31 17:35:58 GMT 2025
Edited
by admin
on Mon Mar 31 17:35:58 GMT 2025
Record UNII
W4193719XR
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
SODIUM DEHYDROCHOLATE
INN   WHO-DD  
INN  
Preferred Name English
DEHYDROCHOLATE SODIUM
Common Name English
Sodium 3,7,12-trioxo-5?-cholan-24-oate
Systematic Name English
DEHYDROCHOLIC ACID SODIUM SALT
MI  
Common Name English
CHOLAN-24-OIC ACID, 3,7,12-TRIOXO-, SODIUM SALT, (5.BETA.)-
Common Name English
sodium dehydrocholate [INN]
Common Name English
DEHYDROCHOLIC ACID SODIUM SALT [MI]
Common Name English
Sodium dehydrocholate [WHO-DD]
Common Name English
DECHOLIN SODIUM
Brand Name English
NSC-756707
Code English
Classification Tree Code System Code
NCI_THESAURUS C66913
Created by admin on Mon Mar 31 17:35:58 GMT 2025 , Edited by admin on Mon Mar 31 17:35:58 GMT 2025
Code System Code Type Description
ChEMBL
CHEMBL514446
Created by admin on Mon Mar 31 17:35:58 GMT 2025 , Edited by admin on Mon Mar 31 17:35:58 GMT 2025
PRIMARY
SMS_ID
100000083547
Created by admin on Mon Mar 31 17:35:58 GMT 2025 , Edited by admin on Mon Mar 31 17:35:58 GMT 2025
PRIMARY
NCI_THESAURUS
C76604
Created by admin on Mon Mar 31 17:35:58 GMT 2025 , Edited by admin on Mon Mar 31 17:35:58 GMT 2025
PRIMARY
DRUG BANK
DBSALT001944
Created by admin on Mon Mar 31 17:35:58 GMT 2025 , Edited by admin on Mon Mar 31 17:35:58 GMT 2025
PRIMARY
CAS
145-41-5
Created by admin on Mon Mar 31 17:35:58 GMT 2025 , Edited by admin on Mon Mar 31 17:35:58 GMT 2025
PRIMARY
EVMPD
SUB10556MIG
Created by admin on Mon Mar 31 17:35:58 GMT 2025 , Edited by admin on Mon Mar 31 17:35:58 GMT 2025
PRIMARY
EPA CompTox
DTXSID00883335
Created by admin on Mon Mar 31 17:35:58 GMT 2025 , Edited by admin on Mon Mar 31 17:35:58 GMT 2025
PRIMARY
MERCK INDEX
m4142
Created by admin on Mon Mar 31 17:35:58 GMT 2025 , Edited by admin on Mon Mar 31 17:35:58 GMT 2025
PRIMARY Merck Index
INN
158
Created by admin on Mon Mar 31 17:35:58 GMT 2025 , Edited by admin on Mon Mar 31 17:35:58 GMT 2025
PRIMARY
NSC
756707
Created by admin on Mon Mar 31 17:35:58 GMT 2025 , Edited by admin on Mon Mar 31 17:35:58 GMT 2025
PRIMARY
FDA UNII
W4193719XR
Created by admin on Mon Mar 31 17:35:58 GMT 2025 , Edited by admin on Mon Mar 31 17:35:58 GMT 2025
PRIMARY
ECHA (EC/EINECS)
205-652-1
Created by admin on Mon Mar 31 17:35:58 GMT 2025 , Edited by admin on Mon Mar 31 17:35:58 GMT 2025
PRIMARY
PUBCHEM
23675007
Created by admin on Mon Mar 31 17:35:58 GMT 2025 , Edited by admin on Mon Mar 31 17:35:58 GMT 2025
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE